BNT111

BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer.

Over 60 mRNA cancer vaccine candidates are in clinical trials, signaling a transformative shift in cancer treatment.

The UK has partnered with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies through clinical trials, leveraging mRNA technology. This collaboration, extending to 2030, also includes the potential supply of commercial therapies and covers infectious disease targets. BioNTech will establish an R&D centre in Cambridge and an office in London, with the possibility of manufacturing investments in the UK.

BioNTech presented clinical data for its bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113, showcasing progress in its oncology pipeline.

The FDA granted fast-track approval to Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, for metastatic melanoma patients who have failed other treatments, marking a significant advancement in cellular immunotherapy.